clinical trial

AB0430 CHARACTERISING AXIAL INFLAMMATION IN PSORIATIC PATIENTS EXCLUDED BY THE ASAS axSpA ENTRY CRITERIA: FINDINGS FROM THE ATTRACT STUDY
A. Agostinelli, V. Paci, I. Cimaroli, R. Sordillo, F. Fiorini, M. Ciferri, M. Carotti, F. Sessa, M. Giannoni, A. Campanati, A. M. Offidani, A. Giovagnoni, G. Polonara, D. Benfaremo, E. Lubrano, G. Moroncini, F. Proft, D. Poddubnyy, M. M. Luchetti

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1469-1470; DOI: 10.1136/annrheumdis-2024-eular.1102
AB0437 SEX- AND TREATMENT-ASSOCIATED OUTCOMES IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS TREATED WITH DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN A PHASE 2 TRIAL
L. Eder, A. Ogdie, S. Banerjee, M. Nowak, T. Lehman, P. J. Mease

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1476; DOI: 10.1136/annrheumdis-2024-eular.1848
AB0458 DEUCRAVACITINIB, A SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN ACTIVE PSA: ASSESSMENT OF DIRECT AND INDIRECT IMPACT ON PAIN AND FATIGUE OUTCOMES BY MEDIATION ANALYSIS IN A PHASE 2 CLINICAL TRIAL
P. J. Mease, L. Eder, A. Ogdie, A. Deodhar, S. Banerjee, Y. M. Jou, M. Nowak, T. Lehman, V. Strand

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1491; DOI: 10.1136/annrheumdis-2024-eular.1841
AB0459 BASELINE (BL) DEMOGRAPHICS AND DISEASE CHARACTERISTICS BY MENOPAUSAL STATUS AND SEX IN PATIENTS FROM A PHASE 2 TRIAL OF DEUCRAVACITINIB, A FIRST-IN-CLASS, ORAL, SELECTIVE, ALLOSTERIC TYROSINE KINASE 2 INHIBITOR, IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS (PsA)
L. Eder, R. Koti, M. J. Colombo, M. Nowak, S. Dahan

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1492; DOI: 10.1136/annrheumdis-2024-eular.1873
AB0469 EFFICACY AND SAFETY OF SECUKINUMAB IN CHINESE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 16 RESULTS FROM A PHASE III, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED BRIDGING STUDY IN CHINA
X. Leng, Y. Liu, L. Tang, L. Sun, J. LI, J. Hu, H. LI, S. Ye, L. Wu, X. Duan, H. Liu, T. LI, Y. Wang, M. Bustamante, S. Kaur, R. Martin, R. Fu, Y. Tian, J. Yang, P. Pellet, X. Zeng

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1498; DOI: 10.1136/annrheumdis-2024-eular.5374
AB0472 EFFICACY OF GUSELKUMAB IN BIONAIVE PSORIATIC ARTHRITIS PATIENTS WITH SEVERE DISEASE ACTIVITY: POST-HOC ANALYSIS OF A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
C. T. Ritchlin, E. Lubrano, M. S. Chimenti, E. Leibowitz, M. Sharaf, E. Rampakakis, F. Nantel, F. Lavie, A. Deodhar

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1499-1501; DOI: 10.1136/annrheumdis-2024-eular.25
AB0473 THE USE OF DISEASE ACTIVITY THRESHOLDS FOR THE PSORIATIC ARTHRITIS IMPACT OF DISEASE (PSAID-12) QUESTIONNAIRE TO ASSESS PATIENT PERCEPTIONS OF DISEASE BURDEN IN PATIENTS WITH EARLY OLIGOARTICULAR PSORIATIC ARTHRITIS TREATED WITH APREMILAST IN THE FOREMOST STUDY
L. Gossec, L. C. Coates, D. D. Gladman, A. Ogdie, P. Nash, D. Poddubnyy, A. Kavanaugh, A. Armstrong, C. Selmi, R. Queiro, C. Deignan, R. Wang, J. Reddy, M. Brunori, P. J. Mease

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1501-1502; DOI: 10.1136/annrheumdis-2024-eular.1243
AB0477 EXPERIENCES AND PERSPECTIVES OF PATIENTS WITH PSORIATIC ARTHRITIS PARTICIPATING IN A RANDOMIZED CONTROLLED TRIAL OF DIETARY INTERVENTIONS
L. Eder, S. Tarannum, K. Bush, S. Cohen, C. Compher, H. Emandoilidis, D. D. Gladman, V. Chandran, J. U. Scher, A. Ogdie

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1504-1505; DOI: 10.1136/annrheumdis-2024-eular.738
AB0480 EARLY FATIGUE IMPROVEMENT WITH GUSELKUMAB ASSOCIATES WITH LONGER TERM DISEASE CONTROL IN PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS REPORTING SUBSTANTIAL FATIGUE: POST HOC ANALYSES OF A SUB-POPULATION OF A PHASE 3, RANDOMIZED, CONTROLLED TRIAL OF GUSELKUMAB IN BIOLOGIC-NAÏVE PATIENTS
N. J. Shiff, D. D. Gladman, X. Baraliakos, M. Starr, R. Ranza, E. Rampakakis, F. Nantel, C. Han, A. Östör, P. J. Mease

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1506-1507; DOI: 10.1136/annrheumdis-2024-eular.2658
AB0490 BIMEKIZUMAB EFFICACY THROUGH 3 YEARS IN PATIENTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS: LONG-TERM POOLED ANALYSIS FROM BE BRIGHT
G. Kokolakis, M. Lebwohl, B. Strober, P. Foley, R. G. Langley, Y. Tada, P. Hampton, L. Davis, S. Wiegratz, B. Hoepken, J. Lambert

Annals of the Rheumatic Diseases Jun 2024, 83 (Suppl 1) 1513; DOI: 10.1136/annrheumdis-2024-eular.5083

Main menu

clinical trial

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

clinical trial

Pages